ADITXT INC

ADTXNASDAQ

🏆 #4376 by market capEarnings Sep 2US Equity

$0.00▼ $0.00 (−16.67%)

🌅 Pre-market$0.00▲ 0.00%Regular close · extended-hours price shown

1h—

24h▼ 16.7%

7d▼ 78.5%

14d▼ 78.5%

30d▼ 78.5%

1y▼ 100.0%

🏦Market Cap

$2M

Small Cap

📈Revenue Growth (YoY)

-74.1%

Declining

📊Gross Margin

19.9%

Thin

💵FCF Margin

—

⚖️P/S Ratio

180.9x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $0.00 – $0.00
52-Week Range: $0.00 – $30,270.24
Volume: $2.47B
Avg Volume: $2.31B
Shares Outstanding: 998.0M
Next Earnings: Oct 13, 2026

Fundamentals Snapshot

Annual Revenue: $3,195
Last Q Revenue: $12,159
P/E Ratio: —
P/S Ratio: 180.9x
EPS (TTM): $-205,055.95
Dividend Yield: —

Why Investors Own ADTX

✓High-growth profile — revenue up +41.8% YoY with expanding US Equity exposure.
✓Healthy economics — 35% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$3,195▲ +44.6% YoY

Gross Margin (TTM)

35.1%▲ +3.7% YoY

Operating Income (TTM)

$307▲ +44.6% YoY

Free Cash Flow (TTM)

$185▲ +44.6% YoY

About ADITXT INC

Aditxt Inc. is an innovative biotechnology company dedicated to transforming healthcare through its proprietary immune modulation and personalized medicine platform. Focused on enhancing immune responses to address chronic diseases and allergies, Aditxt aims to significantly improve patient outcomes. With a robust pipeline of therapeutic candidates supported by comprehensive research and strategic collaborations, the company is poised to be a leader in the rapidly evolving field of immune-based therapies. Aditxt's commitment to scientific advancement and patient-centric solutions positions it at the forefront of immunology and the broader healthcare landscape.

🦦